Case report| Volume 21, P9-10, April 2018

MOG-antibody demyelinating diseases: a case of post-partum severe rhombencephalitis and transverse myelitis

Published:February 08, 2018DOI:


      • MOG-IgG disorders are a clinical spectrum that could involve brainstem.
      • Rhombencephalitis (with transverse myelitis) could be caused by MOG-IgG.
      • Patients with MOG-IgG disorder could recover massively from severe attacks.



      Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) associated disorders present with a spectrum of clinical pictures including brainstem involvement.

      Case report

      A patient with the sudden onset of a post-partum severe rhombencephalitis causing respiratory failure (12 years after a mild transverse myelitis). Despite the aggressive clinical course, she had an impressive recovery after plasmapheresis, and no further relapses on immunosuppression.


      MOG-IgG disorders could relapse several years after onset and involve brainstem. Good prognosis is possible after treatment.


      MOG-IgG (myelin oligodendrocyte glycoprotein antibodies), NMOSD (neuromyelitis optica spectrum disorders), AQP4 (aquaporin-4), LETM (longitudinal extensive transverse myelitis), MRI (magnetic resonance imaging), CE (gadolinium enhancement), CSF (cerebrospinal fluid), ADEM (acute demyelinating encephalomyelitis), FLAIR (Fluid Attenuated Inversion Recovery)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jarius S.
        • et al.
        MOG-IgG in NMO and related disorders: a multicenter study of 50 patients.
        J. Neuroinflamm. 2016; 1: 13-281
        • Jurynczyk M.
        • et al.
        Clinical presentation and prognosis in MOG-antibody disease: a UK study.
        Brain. 2017; 1: 3128-3138
        • Kremer L.
        • et al.
        Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients.
        Mult. Scler. 2014; 20: 843-847
        • Reindl M.
        • et al.
        The spectrum of MOG autoantibody-associated demyelinating diseases.
        Nat. Rev. Neurol. 2013; 9: 455-461
        • Spadaro M.
        • et al.
        Ann. Clin. Transl. Neurol. 2015; 2: 295-301